LON:SAR Sareum - SAR Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 100 -5.00 (-4.76%) (As of 01/27/2023 07:40 PM ET) Add Compare Share Share Today's Range 98.10▼ 108.5050-Day Range 70▼ 117.5052-Week Range 55.10▼ 345Volume80,883 shsAverage Volume125,420 shsMarket Capitalization£68.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlines About Sareum (LON:SAR) StockSareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.Read More Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Email Address SAR Stock News HeadlinesJanuary 23, 2023 | marketwatch.comNON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries DataOctober 25, 2022 | finance.yahoo.comSareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth PlansJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 14, 2022 | msn.comSMALL CAP MOVERS: Property lender Lendinvest sinks 36% to a new low of 64p over risk of falling property prices; Cybersecurity firm Intercede surges 39% - msnNOWOctober 13, 2022 | lse.co.ukGlaxosmithkline News Headlines. GSK Share News. Financial News Articles for Gsk Plc Ord 31 1/4P updated throughout the day. - London South EastOctober 12, 2022 | lse.co.ukNigeria's Forcados crude loadings to restart by end of October - SPDC | Financial News - London South EastOctober 12, 2022 | marketwatch.comSareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares Fall - MarketWatchSeptember 13, 2022 | proactiveinvestors.com.auSmall Cap Feast - Critical Metals, Nightcap, Sareum Holdings, Spectra Systems, Altona Rare Earths and more... - Proactive Investors AustraliaJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…September 13, 2022 | morningstar.co.ukCORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu - MorningstarSeptember 12, 2022 | morningstar.co.ukSareum receives US US Food & Drug Administration approval for Sotyktu - MorningstarJuly 28, 2022 | globenewswire.comSareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update - GlobeNewswireJuly 28, 2022 | finance.yahoo.comSareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational UpdateJuly 12, 2022 | fool.co.ukIs the falling Sareum Holdings share price an exciting opportunity? - Motley Fool UKJuly 11, 2022 | fool.co.ukThe Sareum Holdings share price is down 47%! Is now the time to buy?July 4, 2022 | lse.co.ukSareum News Headlines. SAR Share News. Financial News Articles for Sareum Holdings Plc Ord Gbp 0.0125 updated throughout the day. - London South EastJuly 4, 2022 | morningstar.co.ukIN BRIEF: Sareum notes updated payment terms after GSK buy of SRA737 - MorningstarJuly 4, 2022 | morningstar.comPound Unable to Benefit From Rate Rises Due to Poor UK Outlook - MorningstarJuly 4, 2022 | morningstar.comFTSE 100 Led Higher by Energy Stocks as Oil Prices Rise - MorningstarJuly 4, 2022 | morningstar.comFTSE 100 to Open Higher But Gains Seen Fragile - MorningstarJuly 4, 2022 | marketwatch.comSareum Holdings Says GSK Completes Acquisition of Sierra Oncology - MarketWatchJune 10, 2022 | streetinsider.comForm 6-K Midatech Pharma Plc For: Jun 10 - StreetInsider.comJune 10, 2022 | streetinsider.comMidatech Pharma PLC Announces Retirement of Chairman and Proposed New Chairman - StreetInsider.comJune 10, 2022 | finance.yahoo.comMidatech Pharma PLC Announces Retirement of Chairman and Proposed New Chairman - Yahoo FinanceApril 25, 2022 | finance.yahoo.comCompanies Like Sareum Holdings (LON:SAR) Are In A Position To Invest In GrowthApril 13, 2022 | morningstar.co.ukTRADING UPDATES: Sureserve gets new CFO; Sareum notes GSK buys Sierra - MorningstarApril 13, 2022 | marketwatch.comSareum Holdings Notes Glaxo Purchase of Treatment License Holder Sierra Oncology - MarketWatchSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Email Address SAR Company Calendar Today1/29/2023Next Earnings (Estimated)2/20/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:SAR CUSIPN/A CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio10.46 Quick Ratio10.37 Sales & Book Value Annual Sales£47,204.00 Price / Sales1,442.02 Cash FlowGBX 8.83 per share Price / Cash Flow11.32 Book ValueGBX 6.40 per share Price / Book15.63Miscellaneous Outstanding Shares68,069,000Free FloatN/AMarket Cap£68.07 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Tim J. Mitchell Ph.D. (Age 63)Founder, CEO & Exec. Director Comp: $189.6kDr. John C. Reader Ph.D. (Age 56)Founder, Chief Scientific Officer & Exec. Director Comp: $187.14kAlexandra HarrisonHead of IRMr. Anthony Bunn F.C.M.A.FCMA, Sec.Key CompetitorsECO Animal Health GroupLON:EAHAllergy TherapeuticsLON:AGYFutura MedicalLON:FUMBeximco PharmaceuticalsLON:BXPOpen OrphanLON:ORPHView All CompetitorsInsiders & InstitutionsStephen ParkerBought 19,972 shares on 12/28/2022Total: £1.56 M ($78.00/share)View All Insider Transactions SAR Stock - Frequently Asked Questions How have SAR shares performed in 2023? Sareum's stock was trading at GBX 82.50 on January 1st, 2023. Since then, SAR shares have increased by 21.2% and is now trading at GBX 100. View the best growth stocks for 2023 here. When is Sareum's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 20th 2023. View our SAR earnings forecast. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP), Madagascar Oil (MOIL), Summit Therapeutics (SMMT), Rockhopper Exploration (RKH) and What is Sareum's stock symbol? Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR." How do I buy shares of Sareum? Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Sareum's stock price today? One share of SAR stock can currently be purchased for approximately GBX 100. How much money does Sareum make? Sareum (LON:SAR) has a market capitalization of £68.07 million and generates £47,204.00 in revenue each year. How can I contact Sareum? Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The official website for the company is www.sareum.co.uk. The company can be reached via phone at +44-1223-497700. This page (LON:SAR) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.